Abstract
In an effort to develop a quantitative ligand-binding model for the CB1R, pharmacophore modelling studies were performed on 1-sulfonyl 4-acylpiperazine derivatives. Pharmacophore Alignment and Scoring Engine (PHASE) was used to develop predictive Common Pharmacophore Hypotheses (CPHs) in which a five point pharmacophore with one hydrogen bond acceptor (A), two lipophilic/hydrophobic groups (H) and two aromatic rings (R) as pharmacophoric features was developed. On the basis of statistical values, the best-fitted model was identified and the same alignment was used for CoMFA and CoMSIA studies. The models developed showed an excellent r2 predictive value of 0.879 for CoMFA and 0.764 for CoMSIA. The robustness of the models was validated and the mean activity for test set compounds can estimate external predictivity. The 3D contour maps generated from CoMFA/CoMSIA offer important structural insights and provided interpretable explanation of SAR for the compounds. The obtained results may help in designing analogs with better activity.
Keywords: CB1R, CoMFA, CoMSIA, 3D-QSAR, Endocannabinoid, Obesity, PHASE, ligand-binding model, pharmacophoric features, 3D contour maps, endocannabinoid system, anti-obesity therapeutics, metabolic homeostasis, cannabinoid CB1 inverse agonists, 1-sulfonyl-4-acylpiperazines, 3D-pharmacophore model, GPCR ligand binding modes
Letters in Drug Design & Discovery
Title: Pharmacophore and 3D-QSAR Studies on 1-Sulfonyl-4-acylpiperazines as Selective Cannabinoid-1 Receptor (CB1R) Inverse Agonists
Volume: 8 Issue: 7
Author(s): Vikas N. Telvekar, Lalit B. Thakur, Prashant B. Jagdhane and Yogesh D. Manohar
Affiliation:
Keywords: CB1R, CoMFA, CoMSIA, 3D-QSAR, Endocannabinoid, Obesity, PHASE, ligand-binding model, pharmacophoric features, 3D contour maps, endocannabinoid system, anti-obesity therapeutics, metabolic homeostasis, cannabinoid CB1 inverse agonists, 1-sulfonyl-4-acylpiperazines, 3D-pharmacophore model, GPCR ligand binding modes
Abstract: In an effort to develop a quantitative ligand-binding model for the CB1R, pharmacophore modelling studies were performed on 1-sulfonyl 4-acylpiperazine derivatives. Pharmacophore Alignment and Scoring Engine (PHASE) was used to develop predictive Common Pharmacophore Hypotheses (CPHs) in which a five point pharmacophore with one hydrogen bond acceptor (A), two lipophilic/hydrophobic groups (H) and two aromatic rings (R) as pharmacophoric features was developed. On the basis of statistical values, the best-fitted model was identified and the same alignment was used for CoMFA and CoMSIA studies. The models developed showed an excellent r2 predictive value of 0.879 for CoMFA and 0.764 for CoMSIA. The robustness of the models was validated and the mean activity for test set compounds can estimate external predictivity. The 3D contour maps generated from CoMFA/CoMSIA offer important structural insights and provided interpretable explanation of SAR for the compounds. The obtained results may help in designing analogs with better activity.
Export Options
About this article
Cite this article as:
N. Telvekar Vikas, B. Thakur Lalit, B. Jagdhane Prashant and D. Manohar Yogesh, Pharmacophore and 3D-QSAR Studies on 1-Sulfonyl-4-acylpiperazines as Selective Cannabinoid-1 Receptor (CB1R) Inverse Agonists, Letters in Drug Design & Discovery 2011; 8 (7) . https://dx.doi.org/10.2174/157018011796235284
DOI https://dx.doi.org/10.2174/157018011796235284 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Oncostatin M: Risks and Benefits of a Novel Therapeutic Target for
Atherosclerosis
Current Drug Targets Transmembrane Protein 166 and its Significance
Protein & Peptide Letters Cardiovascular and Renal Outcomes of Incretin-based Therapies: A Review of Recent Clinical Trials
Current Cardiology Reviews Indicators of Cardiovascular Risk in Metabolic Syndrome: Long Term Follow-up in Italian Patients
Current Vascular Pharmacology A Systematic Review on Pharmaceutical Diabetic Care Services in the United Arab Emirates (UAE)
Current Diabetes Reviews Effect of Vitamin D<sub>3</sub> on Lifespan in Caenorhabditis elegans
Current Aging Science Preface
Current Pharmaceutical Design Neuromodulatory and Anti-Inflammatory Ingredient for Sensitive Skin: In Vitro Assessment
Inflammation & Allergy - Drug Targets (Discontinued) Editorial [Disparity in Pharmacotherapies]
Current Drug Therapy Healthy Properties of Garlic
Current Nutrition & Food Science A Review on Screening Models for Potential Therapeutic Candidates and Targets Against SARS-CoV-2
Current Drug Targets Therapeutic Use of Agonists of the Nuclear Receptor PPARγ in Alzheimers Disease
Current Alzheimer Research Podocytes as Target of Vitamin D
Current Diabetes Reviews Management of Primary Aldosteronism: Its Complications and Their Outcomes After Treatment
Current Vascular Pharmacology A Review of the Effects of Gold, Silver, Selenium, and Zinc Nanoparticles on Diabetes Mellitus in Murine Models
Mini-Reviews in Medicinal Chemistry Analysis of Protein Glycation Products by Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry
Current Medicinal Chemistry Vitamin D Deficiency: Universal Risk Factor for Multifactorial Diseases?
Current Drug Targets Therapy of Chronic Hepatitis C in the Era of Nanotechnology: Drug Delivery Systems and Liver Targeting
Mini-Reviews in Medicinal Chemistry Novel Anti-Angiogenic Compounds for Application in Tumor Therapy – COP9 Signalosome-Associated Kinases as Possible Targets
Mini-Reviews in Medicinal Chemistry Unmasking the Many Faces of Giloy (<i>Tinospora cordifolia</i> L.): A Fresh Look on its Phytochemical and Medicinal Properties
Current Pharmaceutical Design